logo
  

Holcim Closes $6.4 Bln Sale Of Indian Business To Adani Group

Holcim Group (HCMLY.PK,HCMLF.PK), a Swiss building materials maker, Friday said it has closed the $6.4 billion sale of its business in India to the Adani Group.

The transaction comprises Holcim's entire 63.11 percent stake in Ambuja Cements Ltd., which owns a 50.05 percent interest in ACC Ltd., as well as its 4.48 percent direct stake in ACC.

Adani Group has acquired Holcim's full stakes in Ambuja Cement at a share price of 385 Indian Rupees and in ACC at a share price of 2,300 Rupees.

It was in mid May that Adani Group announced its agreements to buy Holcim's entire stake in India's Ambuja Cements and ACC.

Holcim now said the deal strengthens its balance sheet and enables the company to continue its acquisition strategy, building on recent investments of over 5 billion Swiss francs in Solutions & Products.

Jan Jenisch, Holcim CEO, said, "This divestment is another step in our transformation to become the global leader in innovative and sustainable building solutions, strengthening our balance sheet and giving us the firepower to continue our acquisition strategy."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. plans to start using American-made processors from the new advanced chip factory in Phoenix, Arizona operated by chip giant Taiwan Semiconductor Manufacturing Co., according to its Chief Executive Officer Tim Cook. At an event in the factory in Arizona, which was attended by U.S. President Joe Biden, it was also announced that TSMC will invest $40 billion in the new factory. Lidl US has recalled its 8.4 oz Favorina branded Advent Calendar, i.e., Premium Chocolate with a Creamy Filling, citing potential Salmonella contamination, the U.S. Food and Drug Administration said. The products were available for sale at Lidl stores between October 12, 2022 and December 5, 2022. They will have a BEST IF USED BY year of 2023, and barcode number of 4056489516965. Vaccine partners Pfizer Inc. and BioNTech SE are seeking emergency use authorization or EUA from the U.S. Food and Drug Administration to offer their bivalent COVID-19 vaccine to children 6 months through 4 years of age. If authorized, the vaccine would be part of a primary series for children in this age group.
Follow RTT